All Relations between Neurofibroma, Plexiform and nf1

Publication Sentence Publish Date Extraction Date Species
Stephanie J Bouley, Andrew V Grassetti, Robert J Allaway, Matthew D Wood, Helen W Hou, India R Burdon Dasbach, William Seibel, Jimmy Wu, Scott A Gerber, Konstantin H Dragnev, James A Walker, Yolanda Sanche. Chemical genetic screens reveal defective lysosomal trafficking as synthetic lethal with NF1 loss. Journal of cell science. 2024-07-17. PMID:39016685. neurofibromatosis type 1, a genetic disorder caused by germline mutations in nf1, predisposes patients to the development of tumors, including cutaneous and plexiform neurofibromas (cns and pns), optic gliomas, astrocytomas, juvenile myelomonocytic leukemia, high-grade gliomas, and malignant peripheral nerve sheath tumors (mpnsts), which are chemotherapy- and radiation-resistant sarcomas with poor survival. 2024-07-17 2024-07-19 Not clear
Hyery Kim, Hee Mang Yoon, Eun Key Kim, Young Shin Ra, Hyo-Won Kim, Mi-Sun Yum, Min-Jee Kim, Jae Suk Baek, Yu Sub Sung, Sang Min Lee, Hyeong-Seok Lim, Byung Joo Lee, Hyun Taek Lim, Dohyung Kim, Jihee Yoon, Hyunwoo Bae, Soojin Hwang, Yun-Ha Choi, Kyung Ah Kim, In Hee Choi, Seung Won Lee, Su-Jung Park, Beom Hee Le. Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro-oncology. 2024-07-08. PMID:38975694. the mek inhibitor, selumetinib, reduces plexiform neurofibroma (pn) in pediatric patients with neurofibromatosis type 1 (nf1). 2024-07-08 2024-07-11 Not clear
Xuyi Yue, Erik Stauff, Shriya Boyapati, Sigrid A Langhans, Wenqi Xu, Sokratis Makrogiannis, Uchenna J Okorie, Azubuike M Okorie, Vinay V R Kandula, Heidi H Kecskemethy, Rahul M Nikam, Lauren W Averill, Thomas H Shaffe. PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer. Pharmaceuticals (Basel, Switzerland). vol 17. issue 6. 2024-06-27. PMID:38931352. plexiform neurofibromas (pnfs) are benign tumors commonly formed in patients with nf1. 2024-06-27 2024-06-29 Not clear
Camille Plante, Teddy Mohamad, Dhanushka Hewa Bostanthirige, Michel Renaud, Harsimran Sidhu, Michel ElChoueiry, Jean-Paul Sabo Vatasescu, Mikael Poirier, Sameh Geha, Jean-Philippe Brossea. Revisiting the NPcis mouse model: A new tool to model plexiform neurofibroma. PloS one. vol 19. issue 6. 2024-06-20. PMID:38900740. nf1 patients frequently develop a benign tumor in peripheral nerve plexuses called plexiform neurofibroma. 2024-06-20 2024-06-23 mouse
Andrea M Gross, Colette Achée, Sarah E Hart, Lindsay Brewer, Andrea Baldwin, Pamela L Wolters, Brigitte C Wideman. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Future oncology (London, England). vol 20. issue 14. 2024-06-13. PMID:38869947. the sprint study included 50 children with neurofibromatosis type 1 (nf1) and plexiform neurofibroma (pn) that could not be removed with surgery. 2024-06-13 2024-06-15 Not clear
Dorea P Jenkins, Brittany Turner-Ivey, Jody Fromm Longo, Steven L Carrol. Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models. Journal of visualized experiments : JoVE. issue 207. 2024-06-03. PMID:38829133. patients with the autosomal dominant tumor susceptibility syndrome neurofibromatosis type 1 (nf1) commonly develop plexiform neurofibromas (pns) that subsequently transform into highly aggressive malignant peripheral nerve sheath tumors (mpnsts). 2024-06-03 2024-06-05 mouse
Archis R Bhandarkar, Shaan Bhandarkar, Dusica Babovic-Vuksanovic, Aditya Raghunathan, Jonathan Schwartz, Robert J Spinne. Precision oncology in neurofibromatosis type 1: quantification of differential sensitivity to selumetinib in plexiform neurofibromas using single-cell RNA sequencing. Journal of neuro-oncology. 2024-05-13. PMID:38739187. selumetinib is an fda-approved targeted therapy for plexiform neurofibromas in neurofibromatosis type 1(nf1) with durable response rates seen in most, but not all patients. 2024-05-13 2024-05-27 Not clear
David Viskochil, Mariusz Wysocki, Maria Learoyd, Peng Sun, Karen So, Azura Evans, Francis Lai, Héctor Salvador Hernànde. Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas. Neuro-oncology advances. vol 6. issue 1. 2024-05-10. PMID:38721358. selumetinib is approved for the treatment of pediatric patients with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn) in multiple countries, including the usa (≥ 2 years). 2024-05-10 2024-05-27 human
Maria Ioannou, Kriti Lalwani, Abiola A Ayanlaja, Viveka Chinnasamy, Christine A Pratilas, Karisa C Schrec. MEK inhibition enhances the antitumor effect of radiation therapy in NF1-deficient glioblastoma. Molecular cancer therapeutics. 2024-05-07. PMID:38714355. loss of nf1 leads to hyperactive ras signaling, creating opportunity given the established efficacy of mek inhibitors (meki) in plexiform neurofibromas and some individuals with lgg. 2024-05-07 2024-05-27 Not clear
Angela C Hirbe, Carina A Dehner, Eva Dombi, Vanessa Eulo, Andrea M Gross, Taylor Sundby, Alexander J Lazar, Brigitte C Wideman. Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. vol 44. issue 3. 2024-05-06. PMID:38710002. in the setting of nf1, mpnsts arise from malignant transformation of benign plexiform neurofibroma and borderline atypical neurofibromas. 2024-05-06 2024-05-27 Not clear
Gerilyn M Olsen, Dawn H Siegel, Olayemi Sokumbi, Yvonne E Chi. Plexiform neurofibroma masquerading as a giant congenital melanocytic nevus. Pediatric dermatology. 2024-04-01. PMID:38561464. the patient was later diagnosed with neurofibromatosis type 1, and the lesion on the back developed a "bag of worms" texture consistent with a plexiform neurofibroma and found to harbor a pathogenic variant in the nf1 gene. 2024-04-01 2024-04-04 Not clear
Bashnona Attiah, Garrett Alewine, Mary-Kate Easter, Robert A Coover, Cale D Fahrenholt. Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Cells at Doses That Do Not Affect Patient-Matched Schwann Cells. Pharmaceutics. vol 16. issue 3. 2024-03-28. PMID:38543265. nf1 patients are susceptible to the development of neurofibromas, including plexiform neurofibromas (pnfs), which occurs in about half of all cases. 2024-03-28 2024-03-30 Not clear
Britt A E Dhaenens, Sarah A van Dijk, Walter Taal, D Christine Noordhoek, Anna Coffey, Stephen P McKenna, Rianne Oostenbrin. The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands. Journal of patient-reported outcomes. vol 8. issue 1. 2024-03-19. PMID:38499890. half of the patients with neurofibromatosis type 1 (nf1) develop one or more tumours called plexiform neurofibromas, which can have a significant impact on quality of life (qol). 2024-03-19 2024-03-21 Not clear
Yahui Han, Biyun Li, Xiaokun Yu, Jianing Liu, Wei Zhao, Da Zhang, Jiao Zhan. Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis. Journal of neurology. 2024-03-19. PMID:38502338. the approval of selumetinib in patients with neurofibromatosis type 1(nf1) and inoperable plexiform neurofibromas (pn) has reshaped the landscape of clinical management of the disease, and further comprehensive evaluation of the drug's efficacy and safety is needed. 2024-03-19 2024-03-23 Not clear
Andrea M Gross, Colette Achée, Sarah E Hart, Lindsay Brewer, Andrea Baldwin, Pamela L Wolters, Brigitte C Wideman. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Future oncology (London, England). 2024-02-22. PMID:38385301. the sprint study included 50 children with neurofibromatosis type 1 (nf1) and plexiform neurofibroma (pn) that could not be removed with surgery. 2024-02-22 2024-02-24 Not clear
Atara Siegel, Robin Lockridge, Kari L Struemph, Mary Anne Toledo-Tamula, Paige Little, Pamela L Wolters, Anne Dufek, Cecilia Tibery, Melissa Baker, Brigitte C Wideman, Staci Marti. Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study. Journal of pediatric psychology. 2024-02-17. PMID:38366576. neurofibromatosis type 1 (nf1) is a genetic cancer predisposition syndrome that can impact multiple organ systems and is associated with plexiform neurofibroma tumors, requiring care from birth through adulthood. 2024-02-17 2024-02-19 Not clear
Atara Siegel, Mary Anne Toledo-Tamula, Staci Martin, Andy Gillespie, Anne Goodwin, Brigitte Widemann, Pamela L Wolter. Written language achievement in children and adolescents with neurofibromatosis type 1 and Plexiform Neurofibromas. Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence. 2024-02-06. PMID:38318699. at three timepoints over six years, children with nf1 and plexiform neurofibromas (pns) completed woodcock-johnson tests of writing mechanics (spelling, punctuation & capitalization, handwriting), written expression of ideas (writing samples), writing speed (writing fluency), and tests of general cognitive ability, executive function, memory, and attention. 2024-02-06 2024-02-09 Not clear
Sofia Sarantou, Nikolaos M Marinakis, Joanne Traeger-Synodinos, Ekaterini Siomou, Argyrios Ntinopoulos, Anastasios Serbi. Genetically confirmed coexistence of neurofibromatosis type 1 and Cherubism in a pediatric patient. Molecular biology reports. vol 51. issue 1. 2024-01-28. PMID:38281202. neurofibromatosis type 1 (nf1) is an autosomal dominant disorder typified by various combination of numerous café-au-lait macules, cutaneous and plexiform neurofibromas, freckling of inguinal or axillary region, optic glioma, lisch nodules and osseous lesions. 2024-01-28 2024-01-31 Not clear
Po-Yuan Huang, I-An Shih, Ying-Chih Liao, Huey-Ling You, Ming-Jen Le. FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. International journal of molecular sciences. vol 25. issue 1. 2024-01-11. PMID:38203448. approximately a quarter of nf1 patients experience the development of plexiform neurofibromas, potentially progressing into malignant peripheral nerve sheath tumors (mpnst). 2024-01-11 2024-01-13 Not clear
Dana K Mitchell, Breanne Burgess, Emily White, Abbi E Smith, Elizabeth A Sierra Potchanant, Henry Mang, Brooke Rodriguez, Qingbo Lu, Shaomin Qian, Waylan Bessler, Xiaohong Li, Li Jiang, Kylee Brewster, Constance Temm, Andrew Horvai, Eric A Albright, Melissa L Fishel, Christine A Pratilas, Steven P Angus, D Wade Clapp, Steven D Rhode. Spatial gene expression profiling unveils immuno-oncogenic programs of NF1-associated peripheral nerve sheath tumor progression. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023-12-21. PMID:38127282. plexiform neurofibromas (pnf) are benign peripheral nerve sheath tumors (pnst) associated with neurofibromatosis type 1 (nf1). 2023-12-21 2023-12-23 Not clear